




EMLc
ATC codes: [P02CA03](#)

Indication	Cysticercosis of central nervous system <span>ICD11 code: <a href="#">1F70.0</a></span>
INN	Albendazole
Medicine type	Chemical agent
List type	Complementary (EML) (EMLc)
Formulations	Oral > Solid > tablet: 400 mg (chewable, scored) ; 200 mg (chewable) (EMLc)
EML status history	First added in 2021 ( <a href="#">TRS 1035</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 
Wikipedia	<a href="#">Albendazole</a> 
DrugBank	<a href="#">Albendazole</a> 

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the listings for albendazole 400 mg chewable tablets on the EML and EMLc be amended to specify that they be scored. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of a new strength formulation (200 mg chewable tablets) to the EMLc for treatment of diseases caused by taeniid cestode cysts.

